Reference : Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involve...
Scientific journals : Article
Life sciences : Biochemistry, biophysics & molecular biology
Human health sciences : Pharmacy, pharmacology & toxicology
http://hdl.handle.net/2268/79621
Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
English
Stresing, Verena [> > > >]
Fournier, Pierrick G [> > > >]
Bellahcene, Akeila mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > GIGA-R : Labo de recherche sur les métastases >]
Benzaid, Ismahene [> > > >]
Monkkonen, Hannu [> > > >]
Colombel, Marc [> > > >]
Ebetino, F Hal [> > > >]
Castronovo, Vincenzo mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Biologie générale et cellulaire >]
Clezardin [ > > ]
2011
Bone
48
2
259-66
Yes (verified by ORBi)
International
1873-2763
1873-2763
United States
[en] Bisphosphonate ; Risedronate ; Zoledronate ; FPPS ; Angiogenesis
[en] Nitrogen-containing bisphosphonates (N-BPs) are widely used to block bone destruction associated with bone metastasis because they are effective inhibitors of osteoclast-mediated bone resorption. More specifically, once internalized by osteoclasts, N-BPs block the activity of farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway. In addition to their antiresorptive activity, preclinical evidence shows that N-BPs have antiangiogenic properties. However, the exact reasons for which N-BPs inhibit angiogenesis remain largely unknown. Using different angiogenesis models, we examined here the effects of zoledronate, risedronate and three structural analogs of risedronate (NE-58025, NE-58051 and NE-10790) with lower potencies to inhibit FPPS activity. Risedronate and zoledronate were much more potent than NE-compounds at inhibiting both endothelial cell proliferation in vitro and vessel sprouting in the chicken egg chorioallantoic membrane (CAM) assay. In addition, only risedronate and zoledronate inhibited the revascularization of the prostate gland in testosterone-stimulated castrated rats. Moreover, as opposed to NE-compounds, risedronate and zoledronate induced intracellular accumulation of isopentenyl pyrophosphate (IPP) in endothelial cells by blocking the activity of the IPP-consuming enzyme FPPS. Thus, these results indicated that N-BPs inhibited angiogenesis in a FPPS-dependent manner. However, drug concentrations used to inhibit angiogenesis, both in vitro and in the CAM and prostate gland assays, were high. In contrast, a low concentration of risedronate (1 muM) was sufficient to inhibit blood vessel formation in the ex vivo rat aortic ring assay. Moreover, NE-58025 (which had a 7-fold lower potency than risedronate to inhibit FPPS activity) was as effective as risedronate to reduce angiogenesis in the rat aortic ring assay. In conclusion, our results suggest that low concentrations of N-BPs inhibit angiogenesis in a FPPS-independent manner, whereas higher drug concentrations were required to inhibit FPPS activity in vivo.
Giga-Cancer
Institut National de la Santé et de la Recherche Médicale ; Université Claude Bernard Lyon-1 ; Alliance for Better Bone Health (Procter & Gamble Pharmaceuticals and Sanofi-Aventis ; Novartis ; Ligue Régionale contre le Cancer ; Recherche sur le Cancer ; Fonds de la Recherche Scientifique (Communauté française de Belgique) - F.R.S.-FNRS
http://hdl.handle.net/2268/79621
10.1016/j.bone.2010.09.035
Copyright A(c) 2010 Elsevier Inc. All rights reserved.

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
(160) STRESING V BONE 2010.pdfPublisher postprint833.43 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.